Non-depleting CD4-specific antibodies such as clone YTS177.9 were found to promote long-lasting T cell tolerance in animal models. Thus, CD4 blockade could represent a promising therapeutic approach for human autoimmune diseases. However, the mechanisms underlying anti-CD4-induced tolerance are incompletely resolved.
Particularly, multiple immune cells express CD4 including Foxp3 In this regard, CD4-specific monoclonal antibodies were shown in the late 1980s to inhibit helper T cell functions . It was soon recognized that their tolerizing activity does not require CD4 + T cell depletion and could have therapeutic potential. Indeed, nondepleting anti-CD4 antibodies including the well characterized mouse-specific rat IgG2a clone YTS177.9 were shown to suppress or even prevent allograft rejection, allergic reactions and autoimmune responses . It should be underlined that this type of anti-CD4-induced tolerance can be induced in various species and is not restricted to a particular antibody clone, suggesting a core mechanism of action. However, the exact mode of action of anti-CD4-induced tolerance remains incompletely defined. This is surprising given that anti-CD4 antibodies are currently entering various clinical trials .
Particularly, it is unclear whether anti-CD4 treatment acts via Foxp3 
Material and Methods

Mice
DEREG , OTI (all C57Bl/6 background), C57Bl/6 and Balb/c mice were maintained at the animal facilities of Twincore (Hanover, Germany) or the Johannes GutenbergUniversity (Mainz, Germany) under specific pathogen-free conditions. Where indicated, WT and DEREG mice were injected i.p. with 1µg DT (Merck) or sterile PBS on two consecutive days and mice were sacrificed one day later for T cell isolation. All experiments were performed in accordance with institutional, state, and federal guidelines.
Anti-CD4 antibodies and flow cytometry
Functional grade αCD4 (clone YTS177.9) and isotype control antibody were purchased from AbD Serotec or BioXcell. Functional grade αCD4 clones RM4-4 and GK1.5 were kindly provided by Dr. Natalia Zietara and Dr. Guenther Bernhard (Hannover Medical School, Hannover). Fc receptors were blocked using αCD16/32 (2.4G2, produced in house). The following antibodies and secondary reagents were purchased from eBioscience: αCD4 (RM4-5 and GK1.5), αCD8α (53-6.7), αCD8β (H35-17.2), αCD25 (PC61.5), αCD30 (mCD30.1), αCD45R/B220 (RA3-6B2), αCD62L (MEL-14), αCD69 (H1.2F3), αCD86 (GL1), αFoxp3 (FJK-16s), αI-A/I-E (2G9), αICOS (7E.17G9), αIFN-γ (XMG1.2), αNK1.1 (PK136), αOX40 (OX-86), αTer119 (TER-119) and appropriate isotype controls. αCTLA-4 (UC10-4B9) was purchased from Biolegend. αCD4 (RmCD4-2) was kindly provided by Dr. Guenther Bernhard (Hanover Medical School, Hannover) and Dr. Elisabeth Kremmer (Helmholtz Center, Munich). αCD4 clones CT-CD4 and YTS191.1.2 were a kind gift from Dr. Ulrich Kalinke (Twincore, Hannover). CTLA-4-and Foxp3 stainings were carried out using the Foxp3 fixation/permeabilization kit (eBioscience). IFN-γ staining was performed after fixation with 2% paraformaldehyde and permeabilization with 0.5% saponin. For human MLR stainings, αCD3ε (SK7) and αCD4 (SK3) were used. Dead cells were labeled by ethidium monoazide photolysis, propidium iodide or DAPI (all from Sigma). Cells were acquired using LSRII (BD) or Cyan (Beckman Coulter) and data were analyzed with FlowJo (Tristar). Live cells were gated and aggregates were routinely excluded by SSC pulse width. Cell sorting was carried out at the Cell Sorting Core Facility of the Hannover Medical School using FACSAria (BD), XDP or MoFlo (both Beckman Coulter) machines. 
Mouse T cell isolation and labeling
ELISA
IFNα contents in culture supernatants were quantified by sandwich ELISA using rat-αIFNα (RMMA-1), rmIFNα, polyclonal rabbit-α-mIFNα (all from PBL Biomedical Laboratories) and HRP-conjugated goat-α-rabbit IgG (Dianova). IL-12/IL-23p40 contents were determined by using the mouse IL-12/IL-23p40 DuoSet kit (R&D Systems) according to the manufacturer's instructions. HRP was revealed using the OptEIA TMB substrate reagent set (BD). After acidification, the optical density was measured at 450nm against 570nm as reference. Standard curves were generated using non-linear regression (R 2 >0.99) and unknown sample values were interpolated using Prism. IFNα levels are expressed as U/ml per 1x10 6 pDCs.
Statistical analysis
Statistical analysis was performed by Prism software using two-tailed Mann Whitney tests. P values <0.05 were considered statistically significant. exposure. In order to study CD4 downmodulation and to faithfully detect anti-CD4-bound T cells, we identified clone RmCD4-2 to be non-competing with clone YTS177.9 for CD4 binding, in contrast to the clones RM4-5, GK1.5, CT-CD4 and YTS191.1.2 (Fig.1a) . This is well in line with previous data showing that the epitopes of RmCD4-2 and YTA3.12 overlap at the membrane-proximal CD4 domains D3/D4, whereas YTS177.9, GK1.5 and YTS191.1 bind to domain D1 . Our data suggest that RM4-5 and CT-CD4 also bind near domain D1 (Fig.1a) . Fluorescently labeled RmCD4-2 was therefore routinely used for all subsequent analyses to avoid any steric hindrance with YTS177.9. Of note, YTS177.9 exposure reduced CD4 expression levels on both Foxp3 (Fig.1b,c) . This anti-CD4-induced CD4 downregulation was more pronounced at 24 hours (Fig.S1 ), yet both Teff and Tregs remained CD4-positive and their frequencies did not change (Fig.1c) . Thus, both Tregs and helper T cells partially downmodulate CD4 expression after the binding of YTS177.9.
Results
Anti-CD4 binding induces CD4 internalization on both
YTS177.9 inhibits CD4 + helper T cell activation in an IL-2-independent fashion
We next utilized mixed leucocyte reactions (MLRs) as a suitable in vitro test system for pathogenic CD4 + T cell activation. This is based on physiological interactions between the T cell recptor (TCR) and MHC-class-II molecules on allogeneic DCs. MLRs can be inhibited by the anti-CD4 clone GK1.5 independent of impairing physical DC -T cell interactions in vitro . Since YTS177.9 recognizes a closely related epitope (Fig.1a) we suspected that this prototypic tolerizing anti-CD4 clone acts in a similar way. Indeed, the early clustering of CD4 + T cells around allogeneic BMDCs was not impaired by YTS177.9 ( Fig.S2) , whereas the proliferation of CD4 (Fig.S4a,b) . Moreover, 200U/ml rhIL-2 exerted full biological activity because 20-fold higher concentrations led to no substantial further increase in CD25 expression (Fig.S4) .
Conversely, addition of neutralizing IL-2 antibody inhibited isotype-treated MLRs, but to a lower degree than did YTS177.9 in untreated control MLRs (Fig.2b,c) . Moreover, anti-IL-2 synergized with YTS177.9 to further inhibit the MLR (Fig.2b,c) . Collectively, these results suggest that the suppression of IL-2 production is not the cause but rather a consequence of the inhibitory effect of YTS177.9 in vitro. (Fig.2a,b) . However, it was not possible to distinguish between de novo induced Tregs and pre-existing thymus-derived Tregs in these experiments. We thus isolated (Fig.3a,b) . However, YTS177.9 treatment failed to enhance or actually inhibited (Fig.3a,b) .
Another possibility is that anti-CD4 stimulation activates the suppressive function of Tregs highly suppressive, as expected (Fig.3c) . Importantly, YTS177.9 alone failed to activate the suppressive function of Tregs (Fig.3c) . In summary, YTS177.9 treatment does not prominently induce, expand or activate Foxp3 (Fig.4b) . DT-treated WT mice served as a control. Strikingly, the inhibitory action of YTS177.9 was completely independent from the presence of Foxp3 + Tregs (Fig.4c) . Similarly, YTS177.9 inhibited the expression of CD25 and CD69 as well as the downregulation of CD62L independent of Foxp3 + Tregs at an earlier time point (Fig.4d) . These results also rule out the possibility that anti-CD4 treatment renders Tregs only suppressive in conjunction with TCR signals, which was formally not tested in the suppression assay (Fig.3c) . To address whether the Treg-independent mechanism is specific to the clone YTS177.9 or of general relevance, we also included clone GK1.5 (recognizing an overlapping epitope; Fig.1a ) and clone RM4-4 (recognizing a distinct epitope; ) in comparative analyses. Rat IgG2 control antibody had no effect on T cell proliferation (Fig.4e) . Importantly, GK1.5 and RM4-4 potently tolerized conventional T cells in the absence of Foxp3 + Tregs (Fig.4e) . All together, our results suggest that multiple anti-CD4 clones act in a Foxp3 + Treg-independent manner. Fig.5b) . Moreover, the upregulation of MHC-class-II and the co-stimulatory molecule CD86 on pDCs were not impaired (Fig.5c) . When CD4 + cDCs were stimulated with B-type CpG-ODN 1826, the production of IL-12/23p40 was also not altered by YTS177.9 (Fig.5d) . To rule out that RmCD4-2 used for CD4 + DC sorting had covered a functional effect, we next performed experiments with untouched gradient-enriched splenic DCs. These consisted of >90% CD11c (Fig.S5a) . In addition to YTS177.9 we also included GK1.5 in these experiments. Interestingly, both YTS177.9 and GK1.5 did not modify the capacity of pDCs to produce IFNα upon stimulation with A-type CpG-ODN 2216 (Fig.5e) and the upregulation of MHC-class-II and CD86 was not impaired (Fig.5f and Fig.S5c) . A similar picture was seen when assessing IL-12/23p40 production and maturation of DCs upon stimulation with B-type CpG-ODN 1826 (Fig.S5b,d,e) . Interestingly, YTS177.9-exposure downmodulated CD4 expression on DCs (Fig.S5f) as on T cells (Fig.1b,c) . (Fig.5g,h ). (Fig.6a) . Accordingly, the absolute numbers of OX40 + and CD30 + T cells were drastically reduced following anti-CD4 tolererization (Fig.6b) .
DC functions are not modulated by anti-CD4 treatment
However, OX40-and CD30 double-deficient T cells could still be efficiently tolerized by YTS177.9 on a Treg-deficient background (Fig.S6a,b) , ruling out a mechanistic contribution of the two receptors in vitro. This does not contradict previous data showing that OX40/CD30 are not required for T cell proliferation but govern T cell survival in vivo . The stronger proliferation of Foxp3-deficient T cells is likely explained by their preactivation since Foxp3-mutant scurfy mice suffer from lethal autoimmunity whereas Foxp3KO x OX40 KO x CD30 KO mice are protected . In this regard, the efficient tolerizing activity of YTS177.9 even on pre-activated autoimmune T cells (Fig.S6 ) is impressive and suggests that anti-CD4 therapy could be effective in Treg-deficient settings such as the human Immunodysregulation, Polyendrocrinopathy, Enteropathy, X-linked (IPEX) syndrome .
We next investigated various additional receptors and also included the anti-CD4 clones GK1.5 and RM4-4 in parallel to YTS177.9. As seen for OX40 and CD30, the frequencies of proliferated CD4 + Foxp3 -T cells expressing the CD28 family co-stimulatory receptors ICOS and CD28 were reduced upon exposure to YTS177.9, GK1.5 and RM4-4 ( Fig.6c and Fig.S7 ). The same was also seen for the inhibitory receptor CTLA-4 ( (Fig.7) .
Importantly, CD4 + helper T cells that were depleted of Tregs could still be substantially inhibited by RPA-T4 (Fig.7 and Fig.S8 ). These results suggest that, similar to the mouse setting, human anti-CD4 antibodies can have tolerizing activity independent of Foxp3 + Tregs. Thus, the Treg-independent mechanism described here appears to be of general relevance because it is observed independent of the CD4 binding site and in both mouse and human systems of T cell activation. established . Interestingly, a recent study reported that anti-CD4 antibody treatment induces tolerance to factor VIII independent of Foxp3 , supporting our findings.
Discussion
The molecular events underlying Treg-independent anti-CD4-dependent tolerance await further analysis. We showed here that YTS177.9 causes CD4 internalization on both However, IL-2 was not involved in the tolerizing process because its supplementation failed to induce T cell proliferation after exposure to YTS177.9. This contrasts with a previous report showing that IL-2 restored T cell proliferation in the presence of GK1.5 . This is surprising given that GK1.5 and YTS177.9 bind to an overlapping epitope.
However, one should note that IL-2 and GK1.5 were added only after T cell activation in that study. Thus, the T cells had presumably upregulated CD25 and were more responsive to IL-2 compared to our setting where CD25 expression is inhibited by YTS177.9.
In addition to CD25 we observed a defective expression of various molecules normally induced upon T cell activation. These include CD69, OX40, CD30, ICOS and CTLA-4.
This picture is in agreement with a general defect in TCR-mediated T cell activation upon anti-CD4 binding. Although the reduced expression of OX40/CD30 was dispensable for primary T cell proliferation in vitro, it may explain in part a possible Foxp3-independent mechanism of action of anti-CD4 antibodies in vivo due to defective T cell survival . antibody RPA-T4 competes with gp120 for CD4 binding , suggesting the recognition of a closely related epitope. In this regard, one concern is that pathogen-specific tolerance may be induced if an anti-CD4 antibody is administered. However, it was previously shown that anti-CD4-induced tolerance is antigen-specific and thus should only address CD4 + T cells that experience simultaneous activation . Whether this is also true for the novel Treg-independent component of anti-CD4-induced tolerance described in this paper remains to be explored. Moreover, the scenario of anti-CD4 administration during an acute or chronic infection, during which pathogen-derived antigens are highly abundant, deserves careful future investigation. Interestingly, a previous study reported that anti-CD4-mediated tolerance is abrogated when CD28-dependent co-stimulatory signals are provided . Moreover, infections can disrupt tolerance at additional layers .
Conclusion
Current dogma established that Foxp3 
